
Opinion|Videos|November 4, 2024
Outcome Measures in Generalized Myasthenia Gravis
Panelists discuss how various outcome measures are utilized in clinical practice to assess and monitor patients with generalized myasthenia gravis.
Advertisement
Video content above is prompted by the following:
- Can you talk about outcome measures in generalized myasthenia gravis and what you use in your practice?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis
2
FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS
3
Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine
4
FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning
5





























